Oruka Therapeutics, Inc. (ORKA)
NASDAQ: ORKA · Real-Time Price · USD
73.99
-2.40 (-3.14%)
At close: Apr 28, 2026, 4:00 PM EDT
74.25
+0.26 (0.35%)
After-hours: Apr 28, 2026, 7:58 PM EDT
Oruka Therapeutics Employees
Oruka Therapeutics had 68 employees as of December 31, 2025. The number of employees increased by 40 or 142.86% compared to the previous year.
Employees
68
Change (1Y)
40
Growth (1Y)
142.86%
Revenue / Employee
n/a
Profits / Employee
-$1,239,853
Market Cap
3.71B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 68 | 40 | 142.86% |
| Dec 31, 2024 | 28 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Legend Biotech | 2,965 |
| Telix Pharmaceuticals | 1,184 |
| ACADIA Pharmaceuticals | 798 |
| Crinetics Pharmaceuticals | 594 |
| Amicus Therapeutics | 511 |
| Travere Therapeutics | 497 |
| Catalyst Pharmaceuticals | 182 |
| Tango Therapeutics | 137 |
ORKA News
- 5 hours ago - Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering - GlobeNewsWire
- 1 day ago - Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering - GlobeNewsWire
- 1 day ago - Oruka Therapeutics Stock Explodes As Psoriasis Data Shows 'Highly Compelling' Skin Clearance - Benzinga
- 1 day ago - Oruka Therapeutics Transcript: Status update - Transcripts
- 1 day ago - Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis - GlobeNewsWire
- 2 days ago - Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on April 27, 2026 - GlobeNewsWire
- 6 weeks ago - Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 weeks ago - Oruka Therapeutics Transcript: Leerink Global Healthcare Conference 2026 - Transcripts